Background: The authors studied the measurement properties of the Parkinson's DiseaseCognitive Rating Scale (PD-CRS) compared with Movement Disorders Society Task Force (MDS-TF) criteria for the diagnosis of dementia in patients with Parkinson's disease. Methods: The sample consisted of 223 patients who were diagnosed in accordance with the United Kingdom Parkinson's Disease Society Brain Bank who were assessed with both the MDS-TF and the PD-CRS criteria (in addition to other instruments) without the assessors' knowledge of previous results. Internal consistency was studied (homogeneity of the items and Guttmann's k values were obtained) in addition to convergent, divergent, and discriminative validity. The receiver operating characteristic curve was obtained, and the cutoff point at which the PD-CRS had the greatest efficiency was analyzed. Results: The internal consistency was shown to be adequate, with a k value of 0.821. A floor effect was observed in 4 of the items (Sustained Attention, Working Memory, Immediate Verbal Memory, and Alternating Verbal Fluency), and 1 item showed a ceiling effect (Clock Copying). The scale adequately discriminated patients with and without dementia (Kruskal-Wallis; P ≤ 0.000). The area under the curve was 0.899. With a cutoff score of 62 (from a possible score of 134), the scale achieved 94% sensitivity and 99% specificity. Conclusions: The PD-CRS has adequate measurement properties and is a valid tool for studying the presence of dementia in patients with Parkinson's disease.Parkinson's disease (PD) is a degenerative disorder of the central nervous system that causes motor and nonmotor symptomatology; the latter includes cognitive deterioration and dementia in up to 40% of cases. Both PD and associated dementia are independent predictors of an elevated risk of mortality in older adults. 1,2The Parkinson's Disease Cognitive Rating Scale (PD-CRS) 3 is a scale used to evaluate cognitive deterioration in patients with PD. Its original validation study demonstrated a sensitivity and specificity of 94% and good internal consistency (Cronbach's a = 0.85). It has been externally validated by investigators other than its authors, demonstrating adequate measurement properties 4,5 ; and, recently, 6 it was stated that the PD-CRS is 1 of the tools designed for evaluating cognitive disorder in patients with PD.The Movement Disorders Society Task Force (MDS-TF), has established diagnostic criteria for dementia in PD 7 and has developed a method for using this tool. 8 The objective of this

The SCOPA-COG has some advantages over the MMP, the most important being a greater discriminative ability. Multilevel hierarchical analysis clarified the necessity of stratifying the PD population according to educational background, years of illness, and H&Y stage when using these scales.

Parkinson's Disease is a neurodegenerative disorder characterized by motor, autonomic, and neuropsychiatric symptoms, among the latter, apathy has been found to be present in up to 70% of patients. The main objective of the present study was to assess the psychometric properties of the Apathy Scale for evaluation of Ecuadorian patients with Parkinson's. This was a cross sectional study, with re-test. There were 73 women (34.5%) in the final sample of 211 patients. Mean age was 67.5 ± 10.2 years, mean length of illness was 7.1 ± 5.5 years, and the mean ldopa dose was 656.1 ± 292.7 mg/day. The mean Apathy Scale score was 12.7 ± 7.1. Reliability: The Guttman's λ obtained was 0.89. The SEM was 2.34 for the AS. The ICC using an absolute agreement definition was: ICC = 0.78 [(95% IC 0.73 − 0.82) f = 4.96; p ≤ 0.000]. Discriminative validity, analyzed with the Kruskal-Wallis statistic and using H&Y stages as segmentation variable registered an X(2) value of p < 0.0001. In conclusion the Apathy Scale proved to have suitable metric attributes in this specific PD patient sample: internal consistency, reliability, stability, and convergent and known-groups validity.

No abstract

Metric attributes of the RSGE-PD-V2.0 in this sample of study resulted in has sufficient and suitable satisfactory. We, therefore, believe that RSGE-PD-V2.0 is easy and a useful and recommendable specific tool for measuring gait disease in PD patients.